<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of clonal stem cell disorders characterized by abnormal hematopoietic differentiation and maturation, which progress toward <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> in approximately 30% of the cases </plain></SENT>
<SENT sid="1" pm="."><plain>Drug metabolism polymorphisms in <z:chebi fb="0" ids="38559">Cytochrome P450</z:chebi> 2B6 (CYP2B6), <z:chebi fb="0" ids="16856">Glutathione</z:chebi> S-transferase (GST) and Dehydrogenase <z:chebi fb="0" ids="36141">Quinone</z:chebi> 1 (NQO1) enzymes and P-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> (<z:chebi fb="14" ids="53218">MDR</z:chebi>-1) could modify enzyme activity </plain></SENT>
<SENT sid="2" pm="."><plain>Thus, the aim of this study was to identify the influence of CYP2B6 G15631T, GSTT1, GSTM1, NQO1 C609T and <z:chebi fb="14" ids="53218">MDR</z:chebi>-1 C3435T polymorphisms on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> progression </plain></SENT>
<SENT sid="3" pm="."><plain>We analyzed 78 MDS patients using the PCR-RFLP and multiplex method </plain></SENT>
<SENT sid="4" pm="."><plain>The frequency of GST deletions and <z:chebi fb="14" ids="53218">MDR</z:chebi>-1 CC genotype was lower in progression-free patients compared to patients with progression; GST: 17% vs. 35% (P=0.018); <z:chebi fb="14" ids="53218">MDR</z:chebi>-1 gene: 19% vs. 48% (P=0.012) </plain></SENT>
<SENT sid="5" pm="."><plain>We also verified the influence of GST deletions and <z:chebi fb="14" ids="53218">MDR</z:chebi>-1 C3435T on patient overall survival and found no significant difference (RR=0.75; P=0.599 and RR=0.79; P=0.594 respectively) </plain></SENT>
<SENT sid="6" pm="."><plain>We concluded that GSTM1 deletion may contribute toward <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> progression probably due to toxic metabolite accumulation which generates cell toxicity and DNA damage </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, <z:chebi fb="14" ids="53218">MDR</z:chebi>-1 C3435T may have a protective effect against <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> progression because the expected lower expression of P-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> would lead to a higher degree of cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>To the best of our knowledge, this is the first study showing the relationship of these polymorphisms with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> progression </plain></SENT>
</text></document>